Doxorubicin- and Trastuzumab-Modified Gold Nanoparticles as Potential Multimodal Agents for Targeted Therapy of HER2+ Cancers

Recently, targeted nanoparticles (NPs) have attracted much attention in cancer treatment due to their high potential as carriers for drug delivery. In this article, we present a novel bioconjugate (DOX-AuNPs-Tmab) consisting of gold nanoparticles (AuNPs, 30 nm) attached to chemotherapeutic agent dox...

Full description

Saved in:
Bibliographic Details
Published in:Molecules (Basel, Switzerland) Switzerland), 2023-03, Vol.28 (6), p.2451
Main Authors: Żelechowska-Matysiak, Kinga, Wawrowicz, Kamil, Wierzbicki, Mateusz, Budlewski, Tadeusz, Bilewicz, Aleksander, Majkowska-Pilip, Agnieszka
Format: Article
Language:English
Subjects:
Antibiotics
Apoptosis
Binding
Breast cancer
Cancer
Cancer therapies
Cell cycle
Cell Line, Tumor
Chemotherapy
Cytotoxicity
Doxorubicin
Doxorubicin - pharmacology
Doxorubicin - therapeutic use
Drug delivery
Drug delivery systems
Drug therapy
Drugs
ErbB-2 protein
FDA approval
Gold
gold nanoparticles
Health aspects
HER2+ cancers
Humans
Internalization
Light scattering
Metal Nanoparticles
Monoclonal antibodies
multimodality
Nanoparticles
Neoplasms - drug therapy
Pertuzumab
Photon correlation spectroscopy
Spheroids
targeted therapy
Transmission electron microscopy
Trastuzumab
Trastuzumab - pharmacology
Trastuzumab - therapeutic use
Tumors
Vehicles
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recently, targeted nanoparticles (NPs) have attracted much attention in cancer treatment due to their high potential as carriers for drug delivery. In this article, we present a novel bioconjugate (DOX-AuNPs-Tmab) consisting of gold nanoparticles (AuNPs, 30 nm) attached to chemotherapeutic agent doxorubicin (DOX) and a monoclonal antibody, trastuzumab (Tmab), which exhibited specific binding to HER2 receptors. The size and shape of synthesized AuNPs, as well as their surface modification, were analyzed by the TEM (transmission electron microscopy) and DLS (dynamic light scattering) methods. Biological studies were performed on the SKOV-3 cell line (HER2+) and showed high specificity of binding to the receptors and internalization capabilities, whereas MDA-MB-231 cells (HER2-) did not. Cytotoxicity experiments revealed a decrease in the metabolic activity of cancer cells and surface area reduction of spheroids treated with DOX-AuNPs-Tmab. The bioconjugate induced mainly cell cycle G2/M-phase arrest and late apoptosis. Our results suggest that DOX-AuNPs-Tmab has great potential for targeted therapy of HER2-positive tumors.
ISSN:1420-3049
1420-3049
DOI:10.3390/molecules28062451